TABLE 4.
The SCOPE Index
| Value | |||
|---|---|---|---|
| Attribute | Traditional Units | SI Units | Points |
| mg/dL | μmol/L | ||
| Total bilirubin | ≤0.6 | ≤11 | 0 |
| 0.7–2.7 | 11.1–46.7 | +1 | |
| 2.8–4.8 | 46.8–82.4 | +2 | |
| ≥4.9 | ≥82.5 | +3 | |
| g/dL | g/L | ||
| Albumin | ≥4 | ≥40 | 0 |
| 3.2–3.9 | 32–39 | +1 | |
| ≤3.1 | ≤31 | +2 | |
| ×103/μL | ×109/L | ||
| Platelet count | ≥225 | ≥225 | 0 |
| 136–224 | 136–224 | +1 | |
| ≤135 | ≤135 | +2 | |
| U/L | U/L | ||
| GGT | ≤100 | ≤100 | 0 |
| 101–249 | 101–249 | +2 | |
| ≥250 | ≥250 | +3 | |
| Cholangiography* | Normal | 0 | |
| Large-duct involvement | + 1 | ||
| Total | |||
| Low risk | 0–3 | ||
| Medium risk | 4–5 | ||
| High risk | 6–11 | ||
The index is the sum of the points attributed to each of the patient’s total bilirubin, albumin, and platelet count.
Positive findings of multifocal large-duct beading and strictures on magnetic resonance or endoscopic retrograde cholangiopancreatography.